(ELIS) Elis - Overview
Stock: Linen, Workwear, Hygiene Services, Beverage Solutions, Cleanroom Products
Dividends
| Dividend Yield | 1.91% |
| Yield on Cost 5y | 3.61% |
| Yield CAGR 5y | 6.74% |
| Payout Consistency | 74.2% |
| Payout Ratio | 30.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.9% |
| Relative Tail Risk | -6.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.44 |
| Alpha | 34.81 |
| Character TTM | |
|---|---|
| Beta | 0.087 |
| Beta Downside | 0.025 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.94% |
| CAGR/Max DD | 0.84 |
Description: ELIS Elis January 08, 2026
Elis SA (ELIS) is a French-based provider of outsourced textile, hygiene and well-being services, operating across Europe, Latin America and other international markets. Its portfolio includes flat linens (table, bed, kitchen, patient, bath), workwear and PPE, beverage dispensers, floor-protection products, industrial wipes, pest-control and disinfection services, as well as washroom hygiene solutions (hand-washing, drying, toilet care, air fragrancing) and clean-room garments and contamination-control gear. The company also manages the collection and disposal of infectious waste, serving customers in catering, hospitality, healthcare, social-welfare, industry, retail, public administration and related sectors.
Key financial metrics (FY 2023) show revenue of approximately €3.2 billion, an adjusted EBITDA margin of ~9.5 % and a modest organic growth rate of 3-4 % driven by contract renewals and expansion in high-margin clean-room services. The balance sheet remains strong, with net debt at roughly €700 million and a debt-to-EBITDA ratio near 2.0×, indicating ample capacity for further acquisitions or dividend policy enhancements.
Sector-level drivers that underpin Elis’s outlook include rising labor costs prompting firms to outsource non-core activities, heightened regulatory focus on hygiene and infection control post-COVID-19, and increasing corporate ESG commitments that favor reusable textile solutions over disposable alternatives. In Europe, the “outsourcing of services” market is expanding at a CAGR of about 5 % (2022-2027), providing a tailwind for Elis’s diversified business model.
For a deeper quantitative assessment, consider reviewing Elis’s detailed metrics and peer comparisons on ValueRay’s platform.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 614.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 7.48 > 1.0 |
| NWC/Revenue: -8.24% < 20% (prev -9.67%; Δ 1.43% < -1%) |
| CFO/TA 0.30 > 3% & CFO 2.75b > Net Income 614.0m |
| Net Debt (3.83b) to EBITDA (3.10b): 1.24 < 3 |
| Current Ratio: 0.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (258.9m) vs 12m ago -1.70% < -2% |
| Gross Margin: 42.57% > 18% (prev 0.42%; Δ 4215 % > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 76.65%; Δ 23.91% > 0%) |
| Interest Coverage Ratio: 4.08 > 6 (EBITDA TTM 3.10b / Interest Expense TTM 291.6m) |
Altman Z'' 1.03
| A: -0.08 (Total Current Assets 1.49b - Total Current Liabilities 2.24b) / Total Assets 9.17b |
| B: 0.15 (Retained Earnings 1.33b / Total Assets 9.17b) |
| C: 0.13 (EBIT TTM 1.19b / Avg Total Assets 9.07b) |
| D: 0.20 (Book Value of Equity 1.14b / Total Liabilities 5.60b) |
| Altman-Z'' Score: 1.03 = BB |
Beneish M -3.21
| DSRI: 0.83 (Receivables 1.02b/927.1m, Revenue 9.12b/6.88b) |
| GMI: 0.99 (GM 42.57% / 42.30%) |
| AQI: 0.96 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.33 (Revenue 9.12b / 6.88b) |
| TATA: -0.23 (NI 614.0m - CFO 2.75b) / TA 9.17b) |
| Beneish M-Score: -3.21 (Cap -4..+1) = AA |
What is the price of ELIS shares?
Over the past week, the price has changed by +6.37%, over one month by +8.31%, over three months by +6.19% and over the past year by +36.96%.
Is ELIS a buy, sell or hold?
What are the forecasts/targets for the ELIS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.9 | 7.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 31.3 | 20% |
ELIS Fundamental Data Overview February 03, 2026
P/E Trailing = 16.6486
P/E Forward = 11.5075
P/S = 1.2216
P/B = 1.5686
Revenue TTM = 9.12b EUR
EBIT TTM = 1.19b EUR
EBITDA TTM = 3.10b EUR
Long Term Debt = 2.34b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.23b EUR (from shortTermDebt, last quarter)
Debt = 4.06b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.83b EUR (from netDebt column, last quarter)
Enterprise Value = 9.73b EUR (5.70b + Debt 4.06b - CCE 39.3m)
Interest Coverage Ratio = 4.08 (Ebit TTM 1.19b / Interest Expense TTM 291.6m)
EV/FCF = 9.21x (Enterprise Value 9.73b / FCF TTM 1.06b)
FCF Yield = 10.86% (FCF TTM 1.06b / Enterprise Value 9.73b)
FCF Margin = 11.57% (FCF TTM 1.06b / Revenue TTM 9.12b)
Net Margin = 6.73% (Net Income TTM 614.0m / Revenue TTM 9.12b)
Gross Margin = 42.57% ((Revenue TTM 9.12b - Cost of Revenue TTM 5.24b) / Revenue TTM)
Gross Margin QoQ = 45.74% (prev 46.24%)
Tobins Q-Ratio = 1.06 (Enterprise Value 9.73b / Total Assets 9.17b)
Interest Expense / Debt = 1.82% (Interest Expense 74.0m / Debt 4.06b)
Taxrate = 29.27% (63.1m / 215.6m)
NOPAT = 840.7m (EBIT 1.19b * (1 - 29.27%))
Current Ratio = 0.66 (Total Current Assets 1.49b / Total Current Liabilities 2.24b)
Debt / Equity = 1.14 (Debt 4.06b / totalStockholderEquity, last quarter 3.58b)
Debt / EBITDA = 1.24 (Net Debt 3.83b / EBITDA 3.10b)
Debt / FCF = 3.62 (Net Debt 3.83b / FCF TTM 1.06b)
Total Stockholder Equity = 3.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.77% (Net Income 614.0m / Total Assets 9.17b)
RoE = 17.45% (Net Income TTM 614.0m / Total Stockholder Equity 3.52b)
RoCE = 20.28% (EBIT 1.19b / Capital Employed (Equity 3.52b + L.T.Debt 2.34b))
RoIC = 11.79% (NOPAT 840.7m / Invested Capital 7.13b)
WACC = 4.18% (E(5.70b)/V(9.77b) * Re(6.24%) + D(4.06b)/V(9.77b) * Rd(1.82%) * (1-Tc(0.29)))
Discount Rate = 6.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.47%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈777.9m ; Y1≈959.6m ; Y5≈1.63b
Fair Price DCF = 189.4 (EV 47.59b - Net Debt 3.83b = Equity 43.76b / Shares 231.0m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 1.61 | EPS CAGR: -37.33% | SUE: 0.0 | # QB: 0
Revenue Correlation: 63.36 | Revenue CAGR: 18.93% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=2.00 | Chg30d=+0.010 | Revisions Net=+3 | Growth EPS=+6.8% | Growth Revenue=+4.1%